Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

User considers making Zix topical solution with ethanol/alcohol for hair loss treatment. Asks if crushing b6 and zinc into stemoxydine is possible.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

PP405 and JXL069 are the same active molecule, suvomipic, but differ in effectiveness due to delivery methods. Grey market versions fail due to improper formulation and stability issues, unlike the clinically engineered Pelage Pharmaceuticals version.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

Breezula is discussed as a potential topical anti-androgen treatment for hair loss, with mixed opinions on its effectiveness and side effects compared to other treatments like finasteride, minoxidil, and RU58841. Some users express skepticism about its long-term efficacy and potential side effects, while others are hopeful for its approval and use in combination with existing treatments.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.